{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T23:27:16Z","timestamp":1790378836472,"version":"4.1.0"},"reference-count":34,"publisher":"BMJ","issue":"3","license":[{"start":{"date-parts":[[2020,3,12]],"date-time":"2020-03-12T00:00:00Z","timestamp":1583971200000},"content-version":"unspecified","delay-in-days":11,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2020,2,12]]},"published-print":{"date-parts":[[2020,3]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To study the occurrence of torsades de pointes (TdP) ventricular tachycardia in relation to use of drugs labelled with TdP risk, using two nationwide Swedish registers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>Prospective register-based cohort study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Setting<\/jats:title>\n                    <jats:p>Entire Sweden.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Participants<\/jats:title>\n                    <jats:p>Persons aged \u226518 years prescribed and dispensed any drug classified with TdP risk during 2006\u20132017, according to CredibleMeds. Persons with a registered TdP diagnosis during the study period, using drugs labelled with known (TdP 1), possible (TdP 2) or conditional (TdP 3) risk at the incident of TdP were examined.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Primary outcome measures<\/jats:title>\n                    <jats:p>Occurrence of TdP in relation to exposure rates for individual drugs with TdP risk.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Secondary outcome measures<\/jats:title>\n                    <jats:p>Concurrent use of more than one TdP-labelled drug in a person with a TdP diagnosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>During the study period, 410 TdP cases using drugs with TdP risk labels at the incident were registered; 205 women and 205 men, mean age 74.0 and 71.5 years, respectively. Antidepressants dominated (129\/410, 30%), followed by antiarrhythmics (17%). Diuretics and gastric acid-secretion inhibitors, with TdP risk related to induction of hypokalaemia or hypomagnesaemia, were used in 56% and 32% of the 410 TdP cases, respectively. Among the most used antidepressants, citalopram with known TdP 1 risk was associated with both a higher absolute number and incidence of TdP per 100\u2009000 users (two to four times), compared with mirtazapine with possible (TdP 2), and sertraline with conditional (TdP 3) risk. Multiple risk factors, including advanced age, cardiovascular disease and treatment with more than one TdP-classified drug, were frequently observed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Antidepressants followed by antiarrhythmics dominated among TdP risk drugs used by adults with TdP diagnosis, the majority being \u226565 years. TdP risk class and concomitant medication should be considered when prescribing antidepressants to older patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2019-034560","type":"journal-article","created":{"date-parts":[[2020,3,13]],"date-time":"2020-03-13T05:20:53Z","timestamp":1584076853000},"page":"e034560","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":39,"title":["Drug use and torsades de pointes cardiac arrhythmias in Sweden: a nationwide register-based cohort study"],"prefix":"10.1136","volume":"10","author":[{"given":"Bengt","family":"Danielsson","sequence":"first","affiliation":[{"name":"Department of Analysis, Swedish National Board of Health and Welfare, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julius","family":"Collin","sequence":"additional","affiliation":[{"name":"Department of Analysis, Swedish National Board of Health and Welfare, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anastasia","family":"Nyman","sequence":"additional","affiliation":[{"name":"Department of Analysis, Swedish National Board of Health and Welfare, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annica","family":"Bergendal","sequence":"additional","affiliation":[{"name":"Department of Analysis, Swedish National Board of Health and Welfare, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Borg","sequence":"additional","affiliation":[{"name":"Department of Analysis, Swedish National Board of Health and Welfare, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"State","sequence":"additional","affiliation":[{"name":"Department of Analysis, Swedish National Board of Health and Welfare, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lennart","family":"Bergfeldt","sequence":"additional","affiliation":[{"name":"Department of Molecular and Clinical Medicine, University of Gothenburg, Goteborg, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9656-4668","authenticated-orcid":false,"given":"Johan","family":"Fastbom","sequence":"additional","affiliation":[{"name":"Department of Analysis, Swedish National Board of Health and Welfare, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2020,3,12]]},"reference":[{"key":"2025120519313184000_10.3.e034560.1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra032426"},{"key":"2025120519313184000_10.3.e034560.2","unstructured":"Cohagan B , Brandis D . Torsades de pointes (Internet). StatPearls Publishing, 2019. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK459388\/"},{"key":"2025120519313184000_10.3.e034560.3","unstructured":"Credible Meds - Available TdP risk categories . Arizona center for education on research on therapeutics. Available: https:\/\/www.crediblemeds.org\/ [Accessed 15 Oct 2019]."},{"key":"2025120519313184000_10.3.e034560.4","doi-asserted-by":"publisher","DOI":"10.1177\/2042098612454283"},{"key":"2025120519313184000_10.3.e034560.5","unstructured":"U.S. Food & Drug . FDA drug safety communication: revised recommendations for Celexa (citalopram hydrobromide) related to a potential risk of abnormal heart rhythms with high doses, 2012. Available: http:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm297391.htm"},{"key":"2025120519313184000_10.3.e034560.6","unstructured":"European medicines agency . Pharmacovigilance Working Party (PhVWP) October 2011 plenary meeting. EMA\/CHMP\/PhVWP\/845939\/2011. Available: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Report\/2011\/10\/WC500117061.pdf"},{"key":"2025120519313184000_10.3.e034560.7","first-page":"228","article-title":"Are ECG monitoring recommendations before prescription of QT prolonging drugs applied in daily practice? The example of haloperidol","volume":"23","author":"Warnier","year":"2014","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2025120519313184000_10.3.e034560.8","doi-asserted-by":"publisher","DOI":"10.1007\/s11096-016-0414-2"},{"key":"2025120519313184000_10.3.e034560.9","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-014-0196-9"},{"key":"2025120519313184000_10.3.e034560.10","unstructured":"Credible Meds www . Clinical factors associated with prolonged QTc and\/or23 TdP. Arizona Center for Education on Research on Therapeutics, 2018. www.QTFactors.org"},{"key":"2025120519313184000_10.3.e034560.11","first-page":"687","article-title":"QTc prolongation by psychotropic drugs and the risk of torsade de pointes","volume":"108","author":"Wenzel-Seifert","year":"2011","journal-title":"Dtsch Arztebl Int"},{"key":"2025120519313184000_10.3.e034560.12","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2018.00363","article-title":"Proton pump inhibitors and serum magnesium levels in patients with torsades de pointes","volume":"9","author":"Lazzerini","year":"2018","journal-title":"Front Pharmacol"},{"key":"2025120519313184000_10.3.e034560.13","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.e977","article-title":"Differential risk of death in older residents in nursing homes prescribed specific antipsychotic drugs: population based cohort study","volume":"344","author":"Huybrechts","year":"2012","journal-title":"BMJ"},{"key":"2025120519313184000_10.3.e034560.14","first-page":"1","article-title":"Antipsychotics and the risks of sudden cardiac death and all-cause death: cohort studies in Medicaid and Dually-Eligible Medicaid-Medicare beneficiaries of five states","volume":"10","author":"Leonard","year":"2013","journal-title":"J Clin Exp Cardiolog"},{"key":"2025120519313184000_10.3.e034560.15","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2011.11030347"},{"key":"2025120519313184000_10.3.e034560.16","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.d4551","article-title":"Antidepressant use and risk of adverse outcomes in older people: population based cohort study","volume":"343","author":"Coupland","year":"2011","journal-title":"BMJ"},{"key":"2025120519313184000_10.3.e034560.17","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1111\/bcp.12829","article-title":"Antidepressants and antipsychotics classified with torsades de pointes arrhythmia risk and mortality in older adults - a Swedish nationwide study","volume":"81","author":"Danielsson","year":"2016","journal-title":"Br J Clin Pharmacol"},{"key":"2025120519313184000_10.3.e034560.18","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2458-11-450","article-title":"External review and validation of the Swedish national inpatient register","volume":"11","author":"Ludvigsson","year":"2011","journal-title":"BMC Public Health"},{"key":"2025120519313184000_10.3.e034560.19","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0067088","article-title":"Drug treatment in older people before and after the transition to a Multi-Dose drug dispensing System\u2013A longitudinal analysis","volume":"8","author":"Wallerstedt","year":"2013","journal-title":"PLoS One"},{"key":"2025120519313184000_10.3.e034560.20","unstructured":"\u00d6ppna j\u00e4mf\u00f6relser . L\u00e4kemedelsbehandlingar, j\u00e4mf\u00f6relser mellan landsting. Socialstyrelsen, 2013: 6\u201313."},{"key":"2025120519313184000_10.3.e034560.21","doi-asserted-by":"crossref","unstructured":"Vandael E , Vandenberk B , Vandenberghe J , et al . Cases of drug-induced torsade de pointes: a review of Belgian cases in the EudraVigilance database. Acta Clin Belg 2017:72385\u201390.","DOI":"10.1080\/17843286.2017.1300217"},{"key":"2025120519313184000_10.3.e034560.22","doi-asserted-by":"publisher","DOI":"10.1055\/s-2007-992147"},{"key":"2025120519313184000_10.3.e034560.23","doi-asserted-by":"crossref","first-page":"641","DOI":"10.2174\/1389200219666171227203225","article-title":"Safety limits of antidepressant use plus combinations: focus on cardiovascular function","volume":"19","author":"Stella","year":"2018","journal-title":"Curr Drug Metab"},{"key":"2025120519313184000_10.3.e034560.24","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.ijcard.2017.05.072","article-title":"Incidence of torsade de pointes in a tertiary hospital population","volume":"243","author":"Vandael","year":"2017","journal-title":"Int J Cardiol"},{"key":"2025120519313184000_10.3.e034560.25","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1017\/S1092852917000402","article-title":"QTc interval in patients with schizophrenia receiving antipsychotic treatment as monotherapy or polypharmacy","volume":"23","author":"Elliott","year":"2018","journal-title":"CNS Spectr"},{"key":"2025120519313184000_10.3.e034560.26","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1113\/JP270526","article-title":"Predicting drug-induced QT prolongation and torsades de pointes","volume":"594","author":"Roden","year":"2016","journal-title":"J Physiol"},{"key":"2025120519313184000_10.3.e034560.27","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1007\/s00228-017-2321-4","article-title":"QT interval prolongation in hospitalized patients on cardiology wards: a prospective observational study","volume":"73","author":"Khan","year":"2017","journal-title":"Eur J Clin Pharmacol"},{"key":"2025120519313184000_10.3.e034560.28","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0199028","article-title":"QTc interval prolongation in critically ill patients: prevalence, risk factors and associated medications","volume":"13","author":"Fernandes","year":"2018","journal-title":"PLoS One"},{"key":"2025120519313184000_10.3.e034560.29","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1111\/bcp.12969","article-title":"High prevalence of risk factors in elderly patients using drugs associated with acquired torsades de pointes chronically in Colombia","volume":"82","author":"Moreno-Guti\u00e9rrez","year":"2016","journal-title":"Br J Clin Pharmacol"},{"key":"2025120519313184000_10.3.e034560.30","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s40266-015-0337-y","article-title":"Prevalence and risk factors associated with use of QT-Prolonging drugs in hospitalized older people","volume":"33","author":"Franchi","year":"2016","journal-title":"Drugs Aging"},{"key":"2025120519313184000_10.3.e034560.31","doi-asserted-by":"publisher","DOI":"10.1002\/pds.1607"},{"key":"2025120519313184000_10.3.e034560.32","doi-asserted-by":"publisher","DOI":"10.1016\/j.psym.2014.09.002"},{"key":"2025120519313184000_10.3.e034560.33","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijcard.2017.09.011","article-title":"Torsade de pointes: the tip of the iceberg","volume":"257","author":"Braillon","year":"2018","journal-title":"Int J Cardiol"},{"key":"2025120519313184000_10.3.e034560.34","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2010.01.001"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2019-034560","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T03:31:39Z","timestamp":1764991899000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2019-034560"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3]]},"references-count":34,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2020,3,12]]},"published-print":{"date-parts":[[2020,3]]}},"alternative-id":["10.1136\/bmjopen-2019-034560"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2019-034560","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3]]}}}